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We have produced a set of bacterial  expression  pro- 
teins  corresponding  to 10 segments of tenascin and  two 
of fibronectin and tested  them  for  heparin  binding  and 
cell  adhesion. We used polymerase  chain  reaction  clon- 
ing to terminate the segments precisely at domain 
boundaries.  Heparin  binding  activity  was  mapped  to 
two  different  tenascin segments: one comprising the 
fourth  and  fifth  fibronectin  type I11 domains, and to 
TNfbg,  the  fibrinogen-like  terminal knob.  TNfbg,  but 
none of the other tenascin segments, also supported 
adhesion of primary  rat  embryo  skin  fibroblasts.  The 
fibroblasts did not spread on TNfbg but remained 
rounded. Cell binding  to  TNfbg  occurred  in  the  pres- 
ence  or absence of divalent  cations  and  was not  inhib- 
ited by RGD peptides,  suggesting that  integrins  are not 
involved. Fibroblast binding to TNfbg was strongly 
inhibited by soluble heparin, by treating  the cells with 
heparitinase,  or by culture  conditions  that  cause  un- 
dersulfation of proteoglycans.  These observations  sug- 
gest  that cell attachment  to  TNfbg is mediated  by  cell 
surface proteoglycans. 
We have also  made  full-length cDNA constructs  for 
the  largest  and smallest  splice variants of human  ten- 
ascin, as well as one  truncated  after  the  14th  epidermal 
growth  factor-like domain, in  the pNUT  mammalian 
cell  expression  vector.  Stably  transfected  baby  ham- 
ster  kidney cell lines  secreted  large  quantities of ten- 
ascin,  and  this  was assembled into normal hexabra- 
chions,  the  arm  length  corresponding  to  the  construct. 
Tenascin is a large glycoprotein prominent in the extracel- 
lular matrix of specific embryonic tissues, tumors,  and healing 
wounds (for review see Ref. 1). Electron microscopy of the 
native molecule  shows a  distinctive six-armed structure 
termed  the hexabrachion (2). Each arm of the hexabrachion 
is  a polypeptide of 220-320 kDa; sequence analysis suggests 
that its elongated structure is based on a series of independ- 
ently folding globular domains (Fig. 1). The domains are 
identified as  three types, based on homology with other  pro- 
teins: epidermal growth factor (EGF)’; fibronectin type I11 
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(FN-111); and fibrinogen (fig).  The number of domains de- 
pends on species and on alternative RNA splicing. The largest 
splice variant of human  tenascin  contains  all domains so far 
identified in all species sequenced (3,  4), so we will use this 
as  the basis for numbering domains and for the nomenclature 
of our recombinant proteins (Fig. 1). The designation of FN- 
I11 domains in Fig. 1 differs from previous sequence papers, 
in which the domains are simply numbered sequentially. The 
advantage of the proposed nomenclature is that  the universal 
domains found in all species and  all splice variants  are des- 
ignated by numbers 1-5 and 6-8. Alternatively spliced do- 
mains, which vary across and within species, are designated 
by letters. In  this nomenclature, the identical number or letter 
can easily be applied to the homologous domains from all 
known species, as well as to a newly discovered tenascin 
homolog (5). This nomenclature has also been proposed by 
Dr. Ruth Chiquet-Ehrismann.’ 
The model diagrammed in Fig. 1 implies that each of the 
sequence repeats folds independently into  a globular domain, 
independent of its position and neighbors. In this case it 
should be possible to obtain  any single domain or series of 
domains as  an independent unit, correctly folded in its native 
structure. The approach we have taken in the present study 
is to define carefully the domain boundaries and  to produce 
the corresponding segments as bacterial expression proteins. 
This approach is predicated on the model of independent 
folding domains, and  its success confirms this model. 
The multidomain structure of the hexabrachion arm sug- 
gests the possibility of multiple independent functions. In 
principle, each of the domains could bind to a different cell 
surface receptor or ECM molecule, producing a variety of 
cellular responses and serving structural functions in the 
ECM. For example, there is evidence that tenascin  binds  to  a 
number of ECM molecules, including fibronectin (6-8), chon- 
droitin sulfate proteoglycans (9-11), heparin (12), and  certain 
forms of syndecan (13), a cell surface proteoglycan. 
Studies of possible cell surface receptors have focused 
largely on cell adhesion assays, with mostly negative or con- 
troversial results. Our laboratory has consistently reported 
that highly purified intact tenascin has no cell adhesion 
activity for a wide variety of cell types tested (6, 14-16). Other 
laboratories have also emphasized that tenascin is a repulsive 
rather than  an adhesive substrate (17-19). However, several 
groups (5, 20-23) have reported a weak adhesion, without the 
cell spreading that characterizes adhesion to fibronectin. In  a 
recent study Saginati et al. (24) suggested that these obser- 
vations of adhesion were  likely due to contaminating fibro- 
nectin or other adhesion molecules and confirmed our conclu- 
sion that highly purified tenascin has no cell adhesion activity 
* Vrucinic-Filipi, N., and Chiquet-Ehrismann, R. (1992) J.  Cell Sci., 
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in  the  standard assays. Alternatively, some of the reported 
adhesion may indicate a weak adhesion site that is only 
revealed under particular assay conditions. 
Cell adhesion to fibronectin-coated plastic probably mimics 
a physiologically important  cell-substrate adhesion, but cell 
adhesion assays can also be used to demonstrate receptor 
ligand interactions. In principle, any cell with receptors to 
tenascin might be expected to bind to tenascin-coated plastic. 
If the interaction is weak, however, it may require a high 
concentration of the active domain, as well as elimination of 
adjacent segments of the hexabrachion arm that may steri- 
cally block or otherwise interfere with the receptor binding. 
I t  is therefore interesting to prepare small segments of the 
tenascin  subunit  and  test  them individually for cell adhesion, 
as well as  other activities. 
One approach for obtaining domains is to use proteases to 
cleave the molecule into defined fragments. An encouraging 
precedent for this approach is the mapping of fibronectin. 
Because fibronectin is available in large quantities,  and be- 
cause  there  are several apparent hinge regions that  are very 
susceptible to proteases, large quantities of defined proteolytic 
fragments have been purified and tested for activity (25). 
Proteolysis of tenascin, however, has been less successful. The 
hexabrachion arms  are readily cleaved near their  attachment 
to the central nodule, but  there  are few other  sites for pref- 
erential cleavage (20, 26, 27). A pool of chymotryptic 65-90 
kDa fragments was reported to have cell adhesion activity 
(20); these fragments were probably from the C-terminal half 
of the hexabrachion arm  but were not precisely mapped. More 
recently, Chiquet et al. (27) isolated a 60-kDa Pronase frag- 
ment, comprising the last three FN-I11 domains and the 
fibrinogen-like terminal knob and found that  it bound heparin 
and also inhibited cell spreading on fibronectin. In the present 
study we confirm the heparin binding of this fragment and 
map  it more precisely; we have not been able to confirm any 
anti-adhesion activity. 
An alternative to proteolysis is to prepare  bacterial expres- 
sion  proteins corresponding to defined segments of the sub- 
unit.  This approach has been used in several studies of fibro- 
nectin (28-31), demonstrating the central role of the RGD- 
containing domain, as well as  the synergistic effect of adjacent 
FN-I11 domains in cell adhesion. One previous study often- 
ascin described bacterial expression proteins of tenascin seg- 
ments fused to @-galactosidase and examined their ability to 
either  enhance or reduce the binding of cells to plastic (23). 
There are two potential problems with this approach to mak- 
ing expression proteins. First,  the tenascin segments are fused 
to the  rather large @-galactosidase, which could either mimic 
or mask activities of the tenascin segments. Second, the fusion 
proteins were constructed by relying on natural restriction 
sites in the tenascin cDNA, which generally results in a 
peptide that terminates within a folding unit. The terminal 
peptide that is missing the rest of its domain might project as 
a denatured sticky end, which  could create solubility problems 
or interfere with activities such as cell adhesion. Site-directed 
mutagenesis has been used to  trim some of the fibronectin 
constructs to  the precisely desired termination (29, 31),  but 
this requires considerable additional manipulation. 
We have  used the polymerase chain reaction (PCR) as the 
basis for producing expression proteins (a)  without fusion to 
another protein and ( b )  with their  termination  points corre- 
sponding precisely to the independently folding domains. 
Using this approach we have produced a collection of bacterial 
expression proteins mapping the distal  three-fourths of the 
hexabrachion arm (Fig. 1) and  tested  them  for heparin binding 
and for cell adhesion. We have also produced two adhesion 
domains from fibronectin: the single FN-I11 domain 10, con- 
taining the RGD sequence (FNfnlO) and a larger segment 
comprising FN-111 domains 7-10 (FNfn7-10), which includes 
the synergetic domains (29, 30) as well. In the present study 
adhesion of rat embryo fibroblasts to these expression pro- 
teins is explored, confirming previous studies for the fibro- 
nectin domains and discovering a new cell binding domain in 
tenascin. 
In addition to  the bacterial expression proteins, we describe 
three constructs producing defined splice variants or trun- 
cated hexabrachions in a mammalian expression system. The 
successful production of the entire  set of bacterial and mam- 
malian expression proteins confirms the generally accepted 
model of the domain structure of the hexabrachion molecule 
and provides an important  set of tools for defining and map- 
ping functional activities of tenascin. 
MATERIALS  AND  METHODS3 
Bacterial and Mammalian Cell Expression Proteins-The cloning, 
expression, and purification of these proteins are described in the 
Miniprint supplement. 
Tenuscin,  Proteoglycans, and Heparitinase-Human tenascin was 
purified from conditioned medium of U-251MG human glioma  cells 
by gel filtration and Mono Q chromatography (16). The large and 
small splice variants  (HxB.L and  HxBS)  and  the truncated HxB.egf, 
produced by BHK cells transfected with the pNUT vectors (see 
Miniprint supplement) were purified by the same protocol. These 
BHK expression proteins were more difficult to purify and frequently 
showed impurities on silver-stained gels  following the Mono Q chro- 
matography, so a third step of glycerol gradient sedimentation was 
generally added. 
Heparin, grade 1 from porcine intestinal mucosa, heparinase I, and 
heparinase I11 (heparitinase) and heparin-Sepharose were obtained 
from Sigma. Mixed cell surface proteoglycans were prepared from 
cultures of rat embryo fibroblasts by Triton X-100 extraction  and ion 
exchange chromatography as described by Bretscher (32). For analy- 
sis of heparin binding, a 5-ml column of heparin-Sepharose was 
loaded with up to 1 mg total protein in 0.05 M Tris, pH 7.9, and eluted 
with a  gradient of  0-0.4 M NaCl in the same buffer. 
Protein Assays and Analysis:  Calculation of Extinction Coeffi- 
cients-Protein concentrations were determined by measuring the 
absorbance at 278 nm. The extinction coefficient for each protein 
was calculated from the amino acid sequence by counting the number 
of Tyr, Trp,  and Cys residues and using the following values for molar 
extinction (33, 34): for Tyr e278 = 1,400,  for Trp e278 = 5,600, and for 
Cys 6278 = 127 for each disulfide bond (2 Cys residues). These values 
are given in  Table I. For comparison, the same calculation for the 
complete sequence of human tenascin (3, 4) gives A2,* = 1.06 for 1 
mg/ml (HxB.L in Table I), which  is  close to  the value 0.97 that we 
determined previously experimentally, using a heated Biuret assay to 
determine absolute protein concentration (26). The calculation for 
human plasma fibronectin gives = 1.41, which is somewhat higher 
than  the value of 1.28 determined by Mosesson and Umfleet (35). 
Note that both the calculated and experimentally determined extinc- 
tion coefficients are based on the mass of the polypeptide chain and 
ignore any contribution from carbohydrate. In general we trust  the 
calculated extinction coefficient rather than  the experimental values 
(34). 
Sedimentation coefficients were estimated by sedimenting purified 
proteins through 15-40% glycerol gradients in 0.2 M ammonium 
bicarbonate. Elution positions were compared with standard proteins 
run in a  separate gradient: cytochrome c at 1.9 S; ovalbumin at 3.5 S; 
bovine serum albumin at 4.6 S; catalase at 11.3 S; and apoferritin at 
17.6 S .  
Electron microscopy  was performed by preparing rotary shadowed 
specimens (36) from the glycerol gradient fractions. Dimensions were 
measured from prints enlarged to X 250,000. TNfn3 and TNmg were 
approximately globular, but one dimension was generally about 25% 
Portions of this paper (including part of “Materials and Methods” 
and  Tables A and B) are presented in  miniprint at  the end of this 
paper. Miniprint is easily read with the aid of a  standard magnifying 
glass. Full size photocopies are included in  the microfilm edition of 
the  Journal  that is available from Waverly Press. 
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larger than the other. The longer dimension was chosen for all 
particles. The reported measurements are averages of  20-50 individ- 
ual particles, selected for being well extended and separated from 
neighbors. The standard deviations were about 3-7%  of the average. 
In all cases the reported dimensions have  been corrected by subtract- 
ing an estimated 1 nm on both sides for the shell of metal (36). 
SDS-PAGE was performed with 5 or  5-20% acrylamide gels under 
reducing conditions. Gels  were stained with Coomassie Blue or with 
silver, depending on the amount of protein loaded. 
Cells and Cell Adhesion Assay-Rat embryo skin fibroblasts were 
prepared from the skin of 17-day rat embryos, as described (16). 
These fibroblasts were  used  between passages 3  and 25. Cell adhesion 
assays were performed as described previously (6). Briefly, wells in 
96-well plates (Falcon 3912)  were coated with the indicated concen- 
tration of the adhesion protein for 1-2 h at 22-37 "C. The wells  were 
washed with PBS and  then incubated with 1 mg/ml heat-denatured 
bovine serum albumin for 1 h to block all remaining protein-binding 
sites on the plastic (6). The evening before the assay, cells were 
detached by adding 0.05% trypsin, 0.53 mM EDTA and replated at 
about one-half confluence. The concentration of active trypsin  in this 
stock was just sufficient to detach the fibroblasts in about 2 min and 
corresponded to about 5-20 pg/ml freshly made trypsin. The next 
day the cells  were again detached, and  the enzyme reaction stopped 
by adding trypsin inhibitor and washing the cells twice with PBS. 
35,000-50,000 cells in 100 p1 of DMEM (Dulbecco's modified Eagle's 
medium with  4.5 g/liter glucose) were added to wells preloaded with 
100 p1 of PBS  and incubated at 37  "C for 1 h. After gentle washing, 
bound cells  were  fixed with 3% paraformaldehyde, stained with 
toluidine blue, and quantitated spectrophotometrically (6). For phase 
contrast microscopy,  cell adhesion was done on Nunc Lab-Tek plastic 
chambered slides. 
The effect of heparin was tested  either by (a)  preincubating the 
TNfbg substrate with soluble heparin in bovine serum albumin and 
washing with PBS before adding the cells or ( b )  adding soluble 
heparin with the cells. The mixed proteoglycans were only tested by 
method a, since it was necessary to wash away the Triton before 
adding the cells (this is identical to  the procedure used by Murray 
and Jensen (37)). In the heparinase treatment the enzymes were 
added at 0.02 unit/ml to  the suspended cells, incubated 60 min at 
37 "C, and  the mixture of cells and enzyme added to  the wells to  test 
for adhesion. The effect of trypsin was tested at 20 and 200 pg/ml, 
stopping the reaction by adding an excess of trypsin  inhibitor  after 2 
min  and washing the cells twice before testing for adhesion. 
Cell Culture for Undersulfation of Proteoglycans-To vary the sul- 
fation of proteoglycans, cells were  grown under three different con- 
ditions (38, 39). In the first group (controls), cells were grown in 
DMEM with 10% heat-inactivated fetal calf serum. In the second 
group, NaC103  was added to 25 mM to cell culture growing in DMEM 
with 10% serum and further grown for 3-20 h at 37 "C. In the  third 
group, cell monolayers growing in DMEM with serum were washed 
twice and grown in sulfate-free DMEM, without serum, for 3-20 h at 
37 "C. At the end of the incubation, no difference in cell  morphology 
was observed among the three groups. Cells  were harvested by trypsin- 
EDTA as described above. Control cells, grown in DMEM with serum, 
were suspended in DMEM, whereas those grown in presence of 
NaC103 or in sulfate-free DMEM were suspended in sulfate-free 
DMEM  and used for attachment assay. 
RESULTS 
Biochemical Characterization of the Bacterial Expression 
Proteins-The nomenclature of the expression proteins is 
indicated  in Fig. 1. The  first two capital  letters (TN or F N )  
indicate  the Rrotein of origin, the lowercase fn indicates  an 
FN-111 domain, and  the numbers and letters indicate which 
domain(s) are included. All of the PCR-derived DNA was 
sequenced, revealing 5 amino acid substitutions. These are 
tabulated in the  Miniprint  supplement.  The yield of protein 
was usually consistent  in  repeated  cultures of a single con- 
struct  but varied  considerably  from one  construct  to  another 
(Table I), from 2.4 to 40 mg/liter of bacteria. All of the 
proteins comprising one or more FN-111 domains were com- 
pletely soluble in  the  bacterial lysates. The purified  expression 
proteins were analyzed by SDS-PAGE,  demonstrating a  high 
level of purity for each  protein (Fig.  2). 
Tenascin: bacterial TNfnl-5 TNfn6-8- 
expression proteins 
TNfnl-3  TNfn3-5 
TNfn3 @ TNfbg 0 
expression proteins 
Fibronectin:  ba erial FNfn7.10 , R(io ccco 
FNfnlO @ 
FIG. 1. A schematic  diagram of the multidomain structure 
of the human hexabrachion. At the central nodule (on the left), 
the N termini of three  arms are joined to form a trimer, and two 
trimers  are connected to form the hexamer. Each arm comprises 14 
EGF domains of 31 amino acids each, 8-15 FN-I11 domains of 91 
amino acids each, and a single fibrinogen-like domain of  215 amino 
acids. The universal FN-111 domains, i.e. those  present  in all splice 
variants, are numbered 1-5 and 6-8. The alternatively spliced do- 
mains, which are inserted between domains 5 and 6, are designated 
by letters; since the first four alternatively spliced domains of human 
tenascin are closely related (52), they are designated Al-A4; the 
remaining alternatively spliced domains are designated B-D. This 
nomenclature can accommodate all known splice variants from all 
species. The repertoire of tenascin bacterial expression proteins we 
have constructed so far is illustrated below the full-length hexabra- 
chion arm. The two fibronectin expression proteins  are also indicated. 
When  sedimented  on glycerol gradients,  all of the  bacterial 
expression proteins remained near the top of the gradient. 
Sedimentation coefficients were estimated for most of the 
proteins  and  are  listed  in  Table I. Theoretical  sedimentation 
coefficients were calculated  by the  method of Bloomfield (40), 
modeling the  different  expression  proteins  as  extended  rods 
of 10-kDa  spherical  domains,  each 3.34 nm  in  diameter.  These 
model values were 1.5, 3.8, and 4.9 S for proteins with 1, 7, 
and  15 domains: reasonably close to  the measured  values  for 
TNfn3,  TNfnA-D,  and  TNfnALL.  We conclude that  each of 
these expression proteins exists in solution as monomers, 
with  the  hydrodynamic  properties  predicted for extended rods 
with the  appropriate  number of globular domains. 
Electron microscopy of the  peak  fractions  from  the glycerol 
gradients showed in every case  particles of the expected size 
and shape (Fig. 3). Dimensions are listed in Table I for a 
representative  sampling of the expression proteins.  Dimen- 
sions  measured by this  technique  are  accurate  to  about 0.2- 
0.4 nm, so the  diameter of TNfn3  is  not  quantitatively  mean- 
ingful (it is simply a small globular domain). The size of 
TNfbg, both as single particles and when observed as the 
terminal  knob of the  hexabrachion  arm,  is significantly  larger 
than would be expected  for a 27-kDa protein, suggesting an 
elongated or complex internal structure. One of the more 
important conclusions  from the  length  measurements is the 
average distance  per FN-I11 domain  in  the  multidomain seg- 
ments. Values of 2.94, 3.40, 3.08, and 3.19 nm  are  obtained 
H. P. Erickson, unpublished calculations. 
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TABLE I 
Physical  and  chemical  characterization of expression proteins 
Protein name M . O  e* sc Sized Yield‘ 
TNfnl-3 30,645 1.14  7.5 
TNfnl-5 50,388 1.22 3.0, 3.2 14.7 6 
FNfnl-8 78,872 1.17  3.2  24.6 8 
TNfnALL 148,288 1.22  4.3 47.9 2.4 
TNfn3 10,142 0.97 -1.7  3.7 6 
TNfn3-5 29,885 1.22 18 (+18 p) 
TNfnA-D(-C) 59,459 1.34 32 (+122 p) 
TNfnA-D 69,434 1.27  3.1,  3.5  23.6 38 (+25  p) 
TNfn6-8 28,502 1.08  22 
TNfhg 26,130 2.00  7.9 28 
FNfnl0 9,928 1.41 20 
FNfn7-10 39,90’2 1.05 33 
HxB.egf 6 X 66,243 0.34  9.8 
HxB.S 6 X 168,967 0.99  10.7 
HxB.L 6 X 238,392 1.07 12.5 
“The  molecular weight of each protein was calculated from the 
deduced amino acid sequence, not including the  initiation  methionine. 
Note  that  the  mammalian expression proteins will also contain  car- 
bohydrate,  not included in the calculated  molecular weight. 
The  extinction coefficient ( e  = A*,,, for 1 mg/ml) was  calculated 
from  the composition of tyrosine, tryptophan,  and cysteine, as de- 
scribed  under  “Materials  and Methods.” 
‘The sedimentation coefficient (in S) was estimated from zone 
sedimentation  through glycerol gradients, compared  with standards. 
Where two values are given these are from separate experiments. 
TNfn3 was behind  the  smallest  standard, so the -1.7 S estimate  is 
less reliable than  the  other values. 
The dimension given (in  nm)  is  the  length for elongated  particles, 
or  the largest  dimension for the globular or slightly  elongated TNfn3 
and TNfbg.  Dimensions  have  been  corrected for the  estimated  1-nm 
shell of metal. 
“ The yield (in mg/liter) is  the  amount of purified protein recovered 
from 1 liter of bacterial culture. The numbers in parentheses are 
additional  protein recovered as a dimer  or polymer (p). 
for segments  with 5,7,8,  and 15 FN-111 domains. The average 
of these, 3.15 nm,  is  our  best  estimate for the average center 
t o  center spacing of the FN-I11 domains. This value is impor- 
tant because the  crystal  structure of TNfn3  (41)  indicated a 
distance of 3.6 nm between the  initial  a-carbons of adjacent 
domains. A tilting of domains  in a zig-zag fashion was sug- 
gested (41) to accommodate the spacing observed here by 
electron microscopy. 
The expression protein TNfbg was the only one  not ob- 
tained  as soluble in  the bacterial lysate. We anticipated  prob- 
lems with this  protein because of the two internal disulfide 
bonds. The  protein was successfully renatured by the  methods 
described in the  Miniprint  supplement  and  as indicated by 
(a) its solubility, ( b )  its  sedimentation  as a uniform peak  near 
3.5 S, ( c )  the  electron microscopy showing discrete globular 
particles (Fig. 3), ( d )  its reactivity  with two mAbs in  enzym- 
linked  immunosorbent  assay of the  protein coated on  plastic 
(data  not  shown),  and  (e)  the absence of any  detectable free 
sulfhydryls (Miniprint  supplement,  Table  B).  This  last meas- 
urement implies that  the 4 Cys residues are completely paired 
in disulfides. 
A  final  indication that  our expression proteins  are correctly 
folded is that two  single FN-I11 domains  and  one  four-domain 
segment have  been  crystallized and diffract to high resolution 
(TNfn3, Ref. 41; FNfnlO?; FNfn7-106). 
Mammalian Expression Proteins-The terms HxB.L and 
HxB.S refer to  the large and small  splice variants produced 
by  BHK cells transfected  with  the  appropriate cDNA con- 
struct in the  pNUT vector  (see Miniprint for details). HxB.egf 
is a truncated molecule that  terminates  after  the  14th  EGF 
‘ H. C. Taylor, unpublished data. 
D. J. Leahy,  unpublished data. 









FIG. 2. SDS-PAGE of purified recombinant proteins. A and 
R are 5-20% acrylamide gradient gels stained with Coomassie Bril- 
liant Blue, and C is a 5% acrylamide gel stained with silver. A ,  the 
first  lane (HxB.U251)  shows human  tenascin purified from U-251MG 
conditioned medium; the second lane shows  molecular weight mark- 
ers, their relative mass in kDa  indicated  on the left. The subsequent 
lanes show the purified  bacterial  expression proteins indicated by the 
labels. B, the first lane shows purified human tenascin, and the 
second and  third  lanes show the large and small  hexabrachion splice 
variants secreted by the  transfected  BHK cell lines. The subsequent 
lanes show the indicated bacterial expression  proteins. C, the recom- 
binant large and small splice variants compared with our  standard 
human  tenascin from U-251MG glioma cells. The lines to  the right 
of the third lane indicate the previously identified bands: a weak 
doublet a t  220 and 230 kDa, the prominent 320-kDa band, and a 
weak 640-kDa  band. The large splice variant HxB.L  corresponds to 
the 320-kDa band  and HxBS  to  the 220-kDa band. D, HxR.egf runs 
as a  broad band a t  -110 kDa  (the  standards indicated by a star  are 
97,116,  and 212 kDa). 
repeat.  More than 90% of the clones  selected for methotrexate 
resistance  secreted  tenascin  into  the medium, and  the  better 
clones of HxBS or HxB.L accumulated 5-8 pg/ml tenascin 
every 3 days (HxB.egf has  not  yet been completely character- 
ized, so we do not know the secretion levels). The secreted 
proteins were purified by  gel filtration,  anion exchange, and 
gradient  sedimentation (16). Each of the  proteins sedimented 
as a single species, the  sedimentation coefficient correspond- 
ing to  the size of the  construct  (Table  I). 
SDS-PAGE confirmed that  the  proteins secreted by cells 
transfected with HxB.L and  HxBS corresponded to  the size 
predicted  for the  constructs (Fig. 2C). Human tenascin  puri- 
fied from U-251MG cells shows the four bands identified 
previously (1, 26, 42): a weak doublet at  220-230 kDa, the 
very prominent  band a t  320 kDa, and a  cross-linked dimer at  
640 kDa. It  is seen that   HxBS corresponds to  the 220-kDa 
smallest splice variant,  and HxB.L corresponds to  the 320- 
kDa  band. HxB.L also  shows the 640-kDa dimer, and HxBS 
shows a -440-kDa dimer on more heavily loaded gels. The 
protein HxB.egf appeared  on reduced SDS-PAGE as a  band 
at  110 kDa (Fig. 2 0 ) ,  substantially above the expected 66 
kDa. We believe this is simply another example of aberrant 
behavior of certain  proteins  on  SDS gels. Since  SDS-PAGE 
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FIG. 3.  Electron  micrographs of selected  recombinant  proteins.  TNfn3 and T N k g  are globular domains, and the others are rod- 
shaped. The lengths are given in Table I. The three mammalian expression proteins, shown in the bottom row, are all assembled into a normal 
hexabrachion structure. HxB.L and HxBS have long and short arms, corresponding to the two major splice variants. HxB.egf, in which the 
subunits are truncated following the EGF domains, has  the expected very short thin arms amputated at the junction of the thick and thin 
segments. 
overestimates  the mass of HxB.egf by 45 kDa, it  seems likely 
that HxB.L and HxB.S are overestimated by a  similar 
amount. 
Electron microscopy of the peak fractions from the gra- 
dients  demonstrated  that  the  recombinant  proteins were fully 
assembled into normal hexabrachions, with HxB.L having 
long arms and HxBS  short  arms (Fig. 3). HxB.egf is also 
assembled into hexabrachions,  with the expected  very short 
thin  arms  and no thick  segment  or  terminal knob (Fig. 3). 
Mapping the  Sites of Heparin Binding-Because it  is known 
that  the  native hexabrachion molecule binds  heparin (12), we 
decided to  test which of the expression proteins  might have 
this activity. Fig. 4 shows the  results of affinity  chromatog- 
raphy of a mixture of expression proteins over  a  column of 
heparin-agarose. In  the low salt buffer  used to load the  pro- 
teins, TNfnl-5 and TNfbg bound to  the column, whereas 
TNfn3,  TNfnA-D,  and  TNfn6-8 did  not.  More  recently (data 
not shown) we have determined that TNfn3-5 bound to 
heparin, whereas TNfnl-3 did not,  thus  mapping  the  heparin- 
binding  site  to FN-I11 domains 4-5. Both  TNfnl-5  and  TNfbg 
eluted at  0.19 M NaCl (Fig. 4), whereas TNfn3-5 eluted a t  
0.27 M NaCl (data  not  shown).  The  intact hexabrachion (both 
large and small variants)  also  eluted a t  about 0.2 M NaCl  from 
our columns, which confirms the 0.2-0.4 M NaCl elution 
reported by Marton  et al. (12). 
Fibroblast Cell Binding to Bacterial Expression Proteins: 
Effects of Heparin  and Proteoglycans-For these experiments 
we used primary  cultures of rat embryo skin fibroblasts. These 
cells adhered  to  and  spread  on  native fibronectin and  on  the 
expression protein FNfn7-10 but did not  adhere  to  the smaller 
fragment FNfnlO (Fig. 5). This is consistent with previous 
studies  demonstrating  that  the  adjacent “synergy” domains 
are required  for substantial fibroblast  adhesion to  the RGD- 
containing domain (29, 30). All of the tenascin expression 
proteins were tested,  and  the fibroblasts  bound  only to TNfbg. 
Notably, the cells did not spread on TNfbg but remained 
rounded (Fig. 5). Cell binding to the TNfbg substrate de- 
pended on the concentration used to coat the protein and 
required about 10  pg/ml to reach  maximal  binding (Fig. 6). 
This is somewhat  more than  the  concentration of many other 
adhesion proteins, which give a saturated cell binding at  1-5 
pg/ml. Even at   the highest coating  concentrations  there was 
no tendency for the fibroblasts to  spread  on TNfbg. The cell 
binding  to  TNfbg was specifically inhibited by a polyclonal 
antibody  against  human  tenascin;  this  same antibody had no 
effect on cell adhesion to fibronectin. 
Several other cell types were tested,  and all of them bound 
to TNfbg, including  NIL.8 M hamster fibroblasts,  normal rat 
kidney (NRK) cells, and several types of endothelial cells. 
To  explore further  the possible involvement of integrins we 
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FIG. 4. Heparin-Sepharose chromatography of recombi- 
nant tenascin  segments. A mixture of recombinant proteins 
(TNfnA-D(-C), TNfnl-5, TNfn6-8, TNfbg, and TNfn3; 100 pg of 
each protein) in 20 mM Tris-HC1, pH 7.9, was loaded on a heparin- 
Sepharose column and bound proteins eluted with a linear gradient 
of 0-0.35 M NaCI. The  lanes are indicated as “Load,” the mixture of 
recombinant proteins; “Flt,” the unbound flow-through proteins 
(TNfnA-D(-C),  TNfn6-8, and TNfn3);  and “Elut 1,2,3,” representing 
fractions 1-3 eluted from the column near 0.2 M NaC1. Molecular 
weight markers on  the left are same as shown in Fig. 2. 
tested  the effects of EGTA  and  EDTA;  most  integrins require 
divalent  cations for binding  their ligand  (43). Neither  chelator 
had  any effect on cell binding a t  concentrations  up  to 2.5  mM, 
suggesting that  the binding is not mediated by an  integrin.  In 
addition,  the  peptide  GRGDSP a t  25 pg/ml had  no effect on 
fibroblast adhesion to TNfbg. We also tested the effect of 
trypsin treatment of the cells prior to plating for the cell 
attachment assay. Adhesion to  TNfbg was not reduced by 
extending  the  time of trypsin  treatment from  2 to  10 min, nor 
by increasing the concentration of trypsin from 20 pg/ml 
(which  was  sufficient to completely detach  the cells in 2 min) 
to 200 pg/ml. We  conclude that  the  attachment molecule on 
the  cell surface is either completely insensitive  to  trypsin,  or 
i t  is replaced from internal  stores  during  the 30-60 min of 
washing  and incubation on  the  substrate. 
Since we had  determined  that  TNfbg  bound  heparin, we 
tested  whether  heparin would affect the  binding of fibroblasts 
to this domain. As shown in Fig. 7, cell binding was extremely 
sensitive to added heparin. 1.0 pg/ml soluble heparin was 
sufficient  to block virtually all cell attachment,  and 0.1 pg/ml 
was  almost as effective. The  inhibition by heparin was first 
demonstrated by adding  it  with  the cells (Fig. 8),  but  identical 
inhibition was obtained when heparin was incubated  with  the 
TNfbg  substrate  and washed away with PBS before adding 
the  cells (Fig. 7).  We  also tested a crude  mixture of cell surface 
proteoglycans, prepared from the cultured cells by Triton 
extraction  and ion  exchange chromatography (32). This  prep- 
aration also inhibited cell attachment  to  TNfbg (Fig. 8). This 
type  preparation of cell surface  proteoglycans inhibited  neural 
cell  adhesion to N-CAM substrates  in a very similar fashion 
(37). Both  heparin  and  the proteoglycan mixture gave effec- 
tive inhibition after extensive  washing of the  substrate with 
phosphate-buffered saline. The mechanism of inhibition 
therefore appears to involve a tight binding of heparin,  or 
heparin-like proteoglycans, to  the  TNfbg  domain, blocking 
the ability of this domain to  bind cells. 
The  strong  inhibition by heparin suggested that  the ligand 
on  the cell surface might be a heparin-like glycosaminoglycan. 
This was further explored by treating cells with the enzymes 
heparinase I and 111. The former is also  referred to  as “hepa- 
rinase”  and  has a  limited but significant  activity  for  heparan 
sulfate proteoglycans  (44). Heparinase 111, also called “hepar- 
itinase,”  has a stronger activity for heparan  sulfate proteogly- 
cans (44). Both enzymes markedly inhibited the ability of 
cells to  adhere  to  TNfbg (Fig. 8). Heparinase I did not affect 
the  ability of cells to  adhere  to fibronectin,  although  heparin- 
ase 111 reduced this adhesion about 40%. 
To  test  further  the role of cell surface  proteoglycans in cell 
attachment  to  TNbg, we grew cells under conditions that 
reduced the  sulfation of proteoglycans (38, 39).  Simply  elim- 
inating  sulfate from the medium for 3-20 h before the assay 
caused a dramatic decrease in cell binding, reducing the 
number of bound cells to 20% of the control (Fig. 9). Adding 
chlorate  to  the medium (in  the presence of the normal  sulfate 
content) reduced the  binding even further.  The effect does 
not  appear  to be on  the general  viability of the cells, because 
the  treated cells excluded trypan blue (97% viable). Moreover, 
the  treated cells adhered  to  and  spread  on fibronectin  almost 
as well as  the  control cells (Fig. 9).  In  our earlier  experiments 
cells were treated with the sulfate-free or  chlorate medium 
for 20 h,  but we subsequently  found that a  3-h treatment was 
equally effective (Fig. 9). If the cells were restored to normal 
medium  for  3 h, adhesion to  TNfbg was fully recovered. This 
suggests that  the proteoglycans  mediating the adhesion may 
be turned over relatively rapidly. 
Heparin Inhibits Hexabrachion-mediated Hemagglutina- 
tion-In our original isolation and characterization of the 
hexabrachion, we noted that it had a strong agglutination 
activity for  formalin-fixed sheep  erythrocytes  (2).  This activ- 
ity was  confirmed by Chiquet-Ehrismann et al. (22),  and  the 
hemagglutination  was  shown to be inhibited by monoclonal 
antibody  TN68 (22). Since  TN68  binds a t  or  near TNfbg, and 
appears to block cell adhesion  much like heparin (see “Dis- 
cussion”), we tested  the ffect of heparin  on hemagglutination. 
We found that  heparin was a powerful inhibitor of hemagglu- 
tination, blocking it  partially a t  1 pg/ml and completely at  
concentrations of 10 pg/ml or above. 
Soluble Expression  Proteins Do Not  Inhibit Cell Attachment 
to TNfbg or Fibronectin-Because several domains of tenascin 
have been reported  to have anti-adhesion activity (23,27,45), 
we tested each of the bacterial expression proteins for the 
ability  to  inhibit cell binding to  TNfbg  substrates.  TNfbg was 
coated  on  plastic at  10  and 25 pg/ml and thoroughly blocked 
with 1%  heat-denatured bovine serum albumin to ensure that 
the  tested  inhibitory  proteins remained in  the solution  phase 
(6).  TNfnl-5,  TNfnA-D, TNfn6-8, and  TNfbg were added 
with the cells a t  concentrations up to 100 pg/ml. None of 
these soluble proteins  had  any effect on binding of fibroblasts 
to  the  TNfbg  substrate.  The inability of soluble TNfbg  to 
compete  for cell binding  to  the  TNfbg  substrate was surprising 
but  not unprecedented  in cell adhesion  studies. The ligand on 
the  substrate may  be present for  multivalent  binding of cells 
and therefore compete much more efficiently than soluble 
univalent ligand  for cell receptors  (46).  Our  primary interest 
in these  experiments, however, was to look for anti-adhesion 
domains  that might explain the weak or  absent binding of 
cells to  intact  tenascin.  None w re found that affected binding 
to TNfbg. Also, none of the soluble proteins  inhibited fibro- 
blast adhesion to  substrates coated  with 1-5 pg/ml fibronec- 
tin. 
Fibroblasts Do Not Bind to HxB.L, HxB.S, or HxB.egf 
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FIG. 5. Attachment   and  spreading  of  rat embryo  sk in   f ib roblas t s  on a substrate   coated  with  recombinant   f ibronect in  or 
tenascin  fragments.  Trypsinized fibroblasts were incubated a t  37 "C for 60 min on  a  plastic  surface  precoated  with the indicated  native 
proteins ( F N  or H x H )  or  recombinant segments. Unattached cells were removed by gentle  washing and  the  attached cells  photographed. Bar, 
100 rm. FN and FNfn7-10 were coated at  5 pg/ml; the  other  proteins were coated a t  20 pg/ml. 
TNfbg(pglm1) 
FIG. 6. Concentration  dependence  of  at tachment  of  f ibro- 
blasts to TNfbg. Falcon 96-well plates were  coated with increasing 
concentrations of TNfbg and blocked with heat-denatured bovine 
serum albumin. Bound cells were quantitated by staining with 1% 
toluidine blue and measuring the  absorbance a t  595 nm  after lysing 
the cells  with SDS. 
Coated on Plastic-As in our previous studies, fibroblasts 
showed absolutely no adhesion to plastic substrates coated 
with  native  tenascin.  The well indicated HxB  in Fig. 5 was 
coated with our usual preparation of human  tenascin from 
the U-251MG human glioma cell line. We tested  the possibil- 
ity  that  the  alternatively spliced segment  TNfnA-D, which 
we have  recently  identified as  inhibiting focal adhesions (45), 
might have an overall anti-adhesion effect, thus over-riding 
the adhesion to TNfbg. Our  short-armed  recombinant hexa- 
brachion, HxBS, which is completely missing this splice 
segment, should have given adhesion if an  inhibitory effect of 
Heparin (uglml) 
FIG. 7. Inhibition of cell adhesion to TNfbg by heparin. 
T N h g  was  coated on  plastic a t  20 pglml, blocked with bovine serum 
albumin,  and  incubated 30 min with the indicated  concentration of 
heparin in PBS. Heparin was removed, the substrate was washed 
with  PBS,  and cells were added. The values for cells attached are 
normalized to  the  control with no  heparin. 
this segment were the  determining factor. However, HxB.S, 
as well as HxB.L and HxB.egf, demonstrated  no  attachment 
of fibroblasts a t  all concentrations tested. 
DISCUSSION 
We have had extremely good results with the PET-11 
bacterial expression  system. Of the 13 proteins we have at- 
tempted  to make,  all 11 segments comprising different  num- 
bers of FN-I11 domains were expressed  in high yield and were 
soluble in the bacterial lysate. We attribute  this success at  
least  partly  to  our PCR protocol, which allowed us to termi- 
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TNltg: 20  pglrnl  Fibronectin: 5 pglrnl 
FIG. 8. Effect of heparin, heparinase, and proteoglycans on 
cell  attachment to substrates of 20 pg/ml TNfbg and 6 pg/ml 
fibronectin. All treatments are  normalized to the control value  for 
untreated cells to the same substrate. In this experiment heparin was 
continuously present with the  cells at 1 pg/ml. In the treatments with 
heparinase I or 111, the enzymes were  added to  the cells at 0.02 unit/ 
ml for 60 min and then the cells added to the substrate in the 
continued presence of enzyme. Mixed cell surface proteoglycans, at 
= 0.39, were incubated on the  TNfbg substrate for 30 min; the 
substrate was  washed to remove unbound proteoglycans and Triton 
before the cells were added. 
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TNlbg: 25 pglrnl Fibronectin: 2.5 Hg/rnl 
FIG. 9. Effect of sulfate depletion and  chlorate  treatment 
on attachment of fibroblasts  to TNfbg and fibronectin sub- 
strates. Fibroblasts were grown in DMEM with 10% serum (closed 
bar), sulfate- and serum-free DMEM for 3 h (crossed bar), or 25 mM 
NaC103 in DMEM with 10% serum for 3 h (open bar). Attachment 
of control cells grown  in DMEM with 10% serum was considered as 
100% and this value was different on fibronectin (A595 = 0.68) and 
TNfbg (A595 = 0.22) substrates. Results represent the mean values of 
adhesion in three wells. The experiment was repeated three times 
with similar results. 
nate each protein at the boundaries of the independently 
folding FN-I11 domains. The success perhaps also reflects the 
extreme  stability of the FN-111 domains, and  the absence of 
any disulfide bonds. Indeed, the  terminal knob domain TNfbg, 
which has two internal disulfides, was completely insoluble in 
the bacterial lysate. However, this domain was easily solubi- 
lized in guanidine HCl and dithiothreitol and  after purifica- 
tion was apparently  renatured to  its native state. We have so 
far failed only with the segment of 14 EGF domains. The 
PET-11 vector containing this construct gave ambiguous in- 
duction of a band of the appropriate size, but  this was rapidly 
degraded and could not be purified. The same construct 
incorporated into  the PET-12 vector (Novagen), which pro- 
duces a secretion protein,  appeared toxic to Escherichia coli. 
We have also had excellent results with the mammalian 
cell expression system, using the  pNUT vector to transfect 
BHK cells. Stably  transfected clones secreted large quantities 
of tenascin into  the medium, which could be purified by our 
standard protocol (16). The recombinant  tenascins were found 
to be fully assembled into normal hexabrachions. This sup- 
ports our earlier conclusion (26) that  the  central knob is made 
up entirely of the six tenascin subunits, rather  than being 
another small protein. These transfected cell lines provide 
sources of the separate large and small splice variants with 
considerable advantages over previous purification by anti- 
body affinity columns (27). The recombinant HxB.egf pro- 
vides a source of the 14 EGF domains free of the FN-111 and 
fbg domains. 
The binding of intact hexabrachion to heparin was first 
demonstrated by Marton et al. (12). More recently Chiquet et 
al. (27) reported heparin binding to a 60-kDa proteolytic 
fragment comprising the distal segment of the hexabrachion 
arm. Our work confirms  these  reports and maps the heparin- 
binding site more precisely to the fibrinogen-like terminal 
knob. In addition, we have discovered a second heparin- 
binding site in FN-111 domains 4-5. Remarkably, although 
both of these segments appear similar in heparin binding 
activity, only TNfbg has a cell attachment activity when 
coated on plastic. 
This cell attachment that we now observe to TNfbg is 
perhaps  related to  the weak adhesion to  tenascin  substrates 
reported by other laboratories (5, 20, 22, 23). Two reports 
seem especially relevant, in that attached cells remained 
rounded, adhesion was not  inhibited by RGD peptides, and 
the activity was mapped near  the TNfbg domain. Spring et 
al. (23)  demonstrated fibroblast adhesion to a fusion protein 
comprising eight FN-I11 domains and TNfbg  (similar to our 
own study  they found no attachment  to  intact tenascin sub- 
strates). Cell attachment  to  the fusion protein was blocked by 
monoclonal antibody  TN68, which they mapped to a  site on 
or near TNfbg (the mapping by electron microscopy could 
not  distinguish between a site on TNfbg or on the adjacent 
TNfn6-8).  Spring et al. (23) concluded that  the adhesion site 
was in the FN-111 domains 7-8, but they did not have a 
separate fusion protein for TNfbg. In our study of the separate 
domains, we found no adhesion at  all to  the expression protein 
TNfn6-8. Our experiments map the adhesion site to the 
adjacent terminal knob domain TNfbg. More recently, NO- 
renberg et al. (5) reported attachment of retinal  neurons to 
both tenascin and to the related protein restrictin (in this 
study they reported adhesion of neural cells to the native 
proteins,  perhaps reflecting the cell type or some subtle dif- 
ference in the adhesion assay). Adhesion to tenascin was 
inhibited by antibody  TN68, and adhesion to restrictin was 
inhibited by a monoclonal antibody that mapped at or near 
its  terminal knob. The adhesion reported in  these  experiments 
is completely consistent with the site that we have mapped to 
TNfbg. Moreover, our observation that heparin blocks the 
hemagglutination activity of intact hexabrachions, and Chi- 
quet-Ehrismann's demonstration that  it is also blocked by 
antibody TN68 (22), suggest that hemagglutination and cell 
attachment may be mediated by the same site on TNfbg. 
The  attachment of fibroblasts to TNfbg is inhibited by four 
different  treatments implicating proteoglycans. ( a )  Heparin, 
either added with the cells, or to  the  substrate before the cells, 
completely blocked cell adhesion at very low concentrations; 
(6 )  a crude preparation of cell surface proteoglycans also 
inhibited cell adhesion; ( c )  treatment of the cells with hepar- 
itinase (and  to a lesser extent with heparinase) blocked adhe- 
sion; and ( d )  cells grown in low sulfate or in  chlorate, which 
blocks sulfation of proteoglycans, lost their ability to bind to 
TNfbg substrates. Our results are complimented by two recent 
studies of heparan  sulfate proteoglycans involved in cell adhe- 
sion to fibronectin or in binding growth factors. 
A recent report by Drake et al. (47) analyzed cell adhesion 
to a  heparin binding peptide from fibronectin, reporting some 
remarkable  similarities to our results. Melanoma cell adhesion 
to  this peptide was totally blocked by 1 pg/ml heparin, the 
same concentration effective against TNfbg. Adhesion was 
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partially blocked by treating the cells with heparitinase at 
0.02 unit/ml, the same used in our study; higher concentra- 
tions gave a  total block. Finally, the cell surface proteoglycan 
that bound this fibronectin peptide was reported to be rapidly 
recirculated, being replaced on the cell surface in  about 15- 
30 min  following trypsin  treatment (47). We observed a  sim- 
ilar rapid recovery in our own experiments, where cells ex- 
posed to 20 or 200  pg/ml trypsin  and  tested for adhesion after 
30-60 min  recovery  were  fully adhesive to TNfbg. Drake et 
al. (47) have isolated the proteoglycan and shown it  to be a 
phosphatidylinositol-anchored heparan sulfate proteoglycan. 
The same or  a related proteoglycan may mediate cell attach- 
ment  to TNfhg. 
Olwin et at. (39) investigated the effect of chlorate  treat- 
ment on cell surface proteoglycans, in particular those in- 
volved in binding and  potentiating the effects of fibroblast 
growth factors. They found that a  chlorate  treatment of only 
2-4 h was sufficient to block completely the binding of fibro- 
blast growth factors to cell surface heparan sulfate proteogly- 
cans  and  to eliminate their mitogenic effects. The rapid time 
course of action is very similar to what we observe for chlorate 
treatment or sulfate depletion to affect cell attachment to 
TNfbg. Previous applications of the chlorate  treatment have 
generally used a 20-h treatment;  these  are the only two studies 
we are aware of investigating the effects at 2-4  h. The impli- 
cation is that  at least some specific  cell surface proteoglycans 
are turning over rapidly enough to be completely replaced by 
their newly synthesized and undersulfated counterparts in the 
2-4-h treatment. 
The proteoglycan syndecan has been suggested as a cell 
surface receptor for tenascin (13), but it is questionable 
whether syndecan is the molecule mediating cell attachment 
to TNfbg. Syndecan isolated from tooth germ organ cultures 
was reported to bind tenascin  but that isolated from cultured 
epithelial cells did not  (13). The  rat embryo skin fibroblasts 
have not been analyzed for syndecan, but syndecan is gener- 
ally expressed at only low levels  on fibroblasts (48). Finally, 
the sensitivity of syndecan to proteases or to spontaneous 
shedding (49) is in contrast to  the stability of the cell attach- 
ment activity of the  rat fibroblasts. 
Why is cell attachment so much weaker to  intact tenascin 
than to the isolated domain, TNfbg? One possibility was an 
anti-adhesion effect exerted by some other domain in the 
intact molecule. The segment TNfnA-D, which we have re- 
cently shown to down-regulate focal adhesions (45), seemed a 
likely candidate. However, the recombinant domain TNfnA- 
D had no effect on adhesion to TNfbg. Furthermore, the 
mammalian recombinant protein HxBS, which is missing 
this segment, had no adhesion activity in our assay. The 
segment TNfn6-8, which  was reported by Chiquet et al. (27) 
to inhibit cell adhesion to fibronectin, was also of interest. 
This domain had no effect in our assays of fibroblast adhesion 
to TNfbg. We conclude that  the weak or absent cell binding 
to intact  tenascin is not due to  an anti-adhesion activity of 
any of the FN-111 domains. 
Our favored explanation for the inhibited cell attachment 
to intact tenascin is steric blocking (6), proposed previously 
as the mechanism for tenascin inhibiting cell adhesion to 
fibronectin. In that study we showed that  the large hexabra- 
chion molecules could bind to the plastic, straddling the 
fibronectin molecules and covering up the cell adhesion sites. 
A similar mechanism could apply to tenascin itself. We have 
observed in the  present study that cell attachment  to  TNfbg 
requires a relatively high concentration, 10 pg/ml,  when coat- 
ing  the plastic. Since this domain constitutes less than 10% 
of the mass of the hexabrachion arm, one might need 100 pg/ 
ml native tenascin to achieve a comparable concentration. 
However,  when the whole hexabrachion is bound to plastic at 
high concentrations, the resulting substrate  is  a dense tangle 
of hexabrachion arms (see calculations in Ref. 6). Most of the 
TNfbg  terminal knobs will  be buried and masked by  overlying 
hexabrachion arms,  rather  than presented to  the cell surface. 
Because of this  steric blocking, it is probably impossible to 
achieve a sufficient density of exposed terminal knobs when 
the whole hexabrachion is coated on plastic. 
Hexabrachion molecules in connective tissue, however, 
should not be subject to  this steric blocking, and even a weak 
binding of the terminal knob to cell surfaces should be im- 
portant. Immuno-electron microscopy suggests that tenascin 
is scattered among the connective tissue fibrils as single 
hexabrachion molecules  (42). The terminal knobs are ideally 
positioned for initial  contact with the surface proteoglycans 
of any cell that contacts them. Binding of these terminal 
knobs to cell surface proteoglycans might serve several roles. 
Cell-cell adhesion is especially attractive in tissues like 
smooth muscle, endothelium, or brain, where cells are close 
enough to be spanned by a single hexabrachion molecule. 
Alternatively, the major role of this  initial binding might be 
as  a  capture mechanism. Thus a weak binding of TNfbg to a 
cell surface proteoglycan could, through cooperativity, greatly 
enhance the binding of FN-I11 or  EGF domains to other cell 
surface receptors. Finally, we note that cell surface heparin- 
like molecules are required for binding of basic fibroblast 
growth factor to  its high affinity receptor (39, 50, 51). Since 
soluble heparin can substitute for the cell surface heparan 
sulfate (50), it may operate by activating or stabilizing an 
active conformation of the growth factor. A similar activation 
of TNfbg by heparan sulfate  or heparin might activate it for 
cell signaling activities not yet identified. 
The  set of expression proteins we have produced and  de- 
scribed here should be of considerable value in identifying 
and mapping functional activities of tenascin. In addition to 
the activities described here, we have already found that 
endothelial cells (but  not fibroblasts) bind to TNfn3;  other 
cells and cellular activities are under investigation. Our pres- 
ent collection of expression proteins should suffice for many 
studies, but new combinations of the FN-I11 domains can be 
produced as needed. The major gap in our collection is the 
segment TNegfl-14, which we have not successfully expressed 
in bacteria. The mammalian expression protein HxB.egf  fills 
this gap. In addition, the mammalian expression proteins 
HxB.S and HxB.L provide an opportunity to  test  the role of 
the alternatively spliced segment in the native hexabrachion 
structure. 
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Cell- and  Heparin-binding  Domains of the  Hexabrachion 
TNfnl-8. This  protek, comprises all of the  FN-Ill domaina of the  smallest splice variant, 
specifidly domains 1-5 and 68. The pmtein WYBB first punfied by an ( N H J Z S O ,  cut (30 - 50% 
saturated),  then  the pellet was resuspended in t r is  bu&r  and  chmmatographed on mono Q , 
where i t  eluted at 0.2 - 0.25 M NaCI. The Dmtein was finallv ourified on heoarin-sepharose, 
where it eluted at 0.16 M NaCI. 
TNfbg. Unlike the other expreasmn proteins. this domain was entirely  in  the insoluble pellet of 
the  baeterial Ivsete. We assumed this was due to inabilitv of the dieulfidea to form mrrfftlv in the 
.. . .  
bacterial &&&m. The &let w.8 washed once with l y k  buffer wntaining  2 M urea  and 
0.02 M Tris-HCI, pH 8.0, mntaining  glutathione (1 mM redueed and  0.1 mM oxidized 
repelleted. rerulting  in significant purification. The pellet was then suspended in  4 M GuHCl in 
glutathione). In a later experiment 10 mM dithiothriotol was used in place of reduced and 
oxidized glutathime, with very aimilar results.  The  suspension was incubated at  4' C overnight 
and then centrifuged. The expreeaion pmtein wan completely solubilized. along with mme 
bacterial proteins. The extract was dialyzed against 6 M urea in 0.02 M Tns-HCI (pH 8.0) 
containing glutathione (or 1 mM WIT). A small preeipitate  sometimes formed at this  point the 
solution wee clarified by centrifugation  and  passed over the Mono Q column. which was 
equilibrated  in  buffer A containing 6 M urea. Gel electrophoresis showed that  the  TNhg protein 
was in the Bow thmugh. while most of the bacterial proteins bound to the column. The flaw 
but mntaining 1 mM glutsthione or IYIT. followed by extensive dialysis  againat lria buffer without thmugh was d i a l y d  slowly (no stirring) againat 0.02 M Tria -HCI, pH 7.9. in the absence of urea 
reducing agent. For some purposes a final purification was performed on hepann-eepharose, 
chromntogmphy on mono S. Initial attempts to chmmstogrsph  the pratean a t  pH 3.5 resultcd m 
from which T N b  eluted et 0.19 M NaCI. Alternatively. a final purifiestion was done by 
total loas  of the pmtein. 10 for TNlbg the mono S waa run at pH 1.9. 11 eluted at 0.06 M NaCI. 
separated from two or three minor mntaminanta. 
bacterial pallet, before the purification over the Mono Q. gave a large precipitate end a very low 
yield of soluble pmlein. We mndude that  it  ia important to purify a protoin while solubilized m 
urea before attempting to renature it. 
protein and the n l a t e  of four cysteine renidues. Protein was allowed to react with 5,5"Pthiobrs-l2- 
The sulhydry l  mntent of TNmg w88 determined to assess the folding of recombinant 
nitrobenmic acid). (DTNB) and the color formed WBB measured at 412 nm (55). Cysteine and 
tubulin w0re uaed a# positive mntmls. Free  sulfhydryls  in TNhg were also quantitated using 4.c. 
bi6-dimethylaminodiphenylca~i"~ (BDC-OH). Thie  reagent forms a calored cation in the 
Presence of guuanidine-HC1 and pH below neutral.  The  intensity of the color decreases when the 
cation mBCte with the sulhydryl groups. This reaction is five tunes more nensitive than  the 
reaction of MNB for detecting sulfhydryl groups (56). Ae shown in Table B. TNhg had no 
detectable free aulhydryle  in  either BBBBY. In separate BBBBYB. TNhg was run on "an-reducmg 
SDSPAGE.  A dimer band  mnetilvting 5.10% of the  total protein could be seen an the  renatured 
Pmtein. but  this WBB removed by mono S chmmatography 
We should note that several attempts to renature TNhg directly from the GuHCI Bolubilired 
2553 
m c a t i o n  deell sdbpeion domains fmm ~%mnmit~ 
FNPnlO. The pmtein WBB firs1 purified fmm the baaend suwrnittant hy an INf{,),SO, cut 
between 50 and 90% saturabon T h e  protem pellet was resuspended nnd chmmatogrsphed on B 
Sephadex G-50 mlumn: FNfnlO  eluted near the included volume and WBB a b u t  90% pure on BDS 
PAGE. The peak fractions were p l e d  and passed over the mono Q column. FNfnlO did not bind 
to the mono Q in 0.02 M lris. pH 7.9, and this flow-thmugh fraction was pure judged by S D S  
PAGE. This fraction was used for m e t  biological assays. A final step of punfication  pnor to 
crystallization was achieved by chmmatography on mono 6, eluting  with B gradient fmm 0 - 0.3 
M NaCl in 0.02 M sodium formate. pH 3.5. FNfnlO eluted 88 a single peak at 0.21 M NaCl in Borne 
oreosrations. and as two ne&. a t  0 21  and 0.23  M NaCI. in others. The second oeak i e  
bre&abli~&&ing the b-for&methionine. 
FNL7-10. The protein was p?eeipitated horn the bacterial supematant st 40% saturated 
(NH.).SO.. and ChromatoeraDhed an mono Q, where i t  eluted at 0.2 M NaCI. SDS-PAGE 
FNhlO has been crystallized (H. C. Taylor et  SI., in  preparation). 
.& . . .  
indicated the protein was ,904, pure fallowing mono Q. For some purpose8 the  protein wae 
dialyzed into d u m  formate. pH 3.5 and  ehmmatographed on mono S. where i t  eluted at 0.43 M 
NaCI. 
FNhl-10 has been crystallized (D. J. Leahy, e t  al., in  preparation). 
M n m m s l i s n e r p r e r d o n ~ t o r ~ r m s l l ~ ~ t e d ~ l r  
Clones mvenng the enltre coding eequenee af hwnsn tenasnn were generously pmnded by 
our wart were A phage HTl2. end MI3 phages HT26 and HT24A.B. and C (the  three M I 3  phages 
Dr. L. Zardi, lstituto Naziansle per la Rice- eul Csnem, Genaa, Italy (4). The elone. used for 
mver the 1 phage HT24. which is cut at two internal EmRl  sites). To produce the smaller splice 
variant, we used the plasmid p31 (57). which WBB generously provided by Dr. K. Stefansson. 
Department of Neuropathology. University of Chicago. and which is missing the  even FN-III 
domains of the  alternatively sphced segment. 
Three  plasmids were constructed by e n e s  of 3-piece ligations. First,  the coding segments 
fmm each of the A and M13 phages were ligated into plasmid Blue SFript (PES, Stratagene), at the 
eeoRI site. Plasmid pBSHxB.L. whtch contains the eomplete coding sequence for the largest 
splice variant. was eonstructed by splicing together the five clones fmm Zardi. The restriction 
sites u t i l i 4  for this mnstruetion WDR BstBl Q 110; Xbal Q 2253, Sac11 0 3159 EmRI B 4111: 
Ndel 0 6111. Plasmid pBS-HrB.S. whlch mdes for the smaller splice variant. used the Stefansaon 
clone p31 to supply the segment between the Xbal and NdeI sites. Plasmid pBSHxB.egf used the 
PCR derived clone TNegfl-14 (Table A), originally designed for the bacterial expression vector, to 
supply the  stop d o n  at base pair 1912. The d i n g  sequence between the RstBl B 710 and an 
Aval 0 1866 WBB replaced by cloned DNA from pBS-HxB.L. in  order to eliminate possible ermrs 
introduced by PCR. HrB.egf. .L and .$ all contain the 3' untrenslated aegrnent present in the 
Zsrdi done HT24C. 
The constructs in pRS were all canfirmed by restriction analysis to have the  pmper size. 
They were then cut fmm pBS at the Not1 end Kpnl sites flanking the construct. The fragments 
were blunted with Klenow reagent. The mammalian expression vector pNUT (581. kindly 
supplied by Dr. Richard D. Pahteer.  Department of Bioehemiatry. Univeraity of Wsehingon. was 
cut with BamHl  and  blunted. The blunted tenaacin eonstructa were ligated into the  pNU" vector. 
and clones having the correct onentation were identified by restriction analysis. Tranafechon of 
BHK fells by the calcium phosphate pracedure and selection of wlonies in  methotrexate fallowed 
standard protoml8, a8 descnbed m B previous application of the pNUT vector (59). 
Notes: For cysteine  atandards  the reaction was developed for only 5 m i " .  All 
other  reactions were developed for 30 mi" before reading  the color. 
